Yes, that's the one that is the most apparent, and from our perspective and our work with Ghana, it has been the biggest obstacle to accessing this legislation. There seems to be a perception, perhaps amongst generic companies and others, that the African countries are going to come to Canada—perhaps sitting down with a company in a room—to talk about specifically what medicines they need.
From the foreign government perspective, from the Ghanaian perspective, that cannot happen, as it's a violation of their domestic laws. So it has to happen the other way around: our companies here have to approach them with the licence in hand.